Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases

December 06, 2024 11:07 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND). The ARGO HT System along with the NULISA™ Platform are designed to revolutionize biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy.

Hong Kong Center for Neurodegenerative Diseases
Hong Kong Center for Neurodegenerative Diseases

"Expansion of the ARGO HT installed base to the APAC region represents a significant step forward in our vision to bring transformative proteomics solutions to researchers worldwide," said Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. "We are excited to contribute to HKCeND's vibrant scientific community and support groundbreaking advancements in the fight against neurodegenerative diseases."

Prof. Nancy Ip, the Director of Hong Kong Center for Neurodegenerative Diseases (HKCeND), added, "The integration of the NULISA Technology enabled by the ARGO HT System into our research infrastructure is a game-changer. This technology will allow us to explore the proteomic underpinnings of neurodegenerative diseases in ways that were previously unimaginable."

The partnership with HKCeND will focus on unlocking new insights into the molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease, and Parkinson's disease. The ARGO HT System and NULISA Platform deployments will empower HKCeND's researchers to identify novel biomarkers, accelerate drug development, and improve early detection and personalized treatment strategies for patients.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

About Hong Kong Center for Neurodegenerative Diseases
The Hong Kong Center for Neurodegenerative Diseases (HKCeND) is a leading research institution dedicated to advancing the understanding and treatment of neurodegenerative disorders. By fostering interdisciplinary collaborations and leveraging state-of-the-art technologies, HKCeND aims to make transformative contributions to global neuroscience.

Alamar's ARGO HT System installed at the Hong Kong Center for Neurodegenerative Diseases
Alamar's ARGO HT System installed at the Hong Kong Center for Neurodegenerative Diseases

 



Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.